{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:17:23Z","timestamp":1778771843712,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["11050"],"award-info":[{"award-number":["11050"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.tvjl.2012.12.016","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T20:48:11Z","timestamp":1359492491000},"page":"536-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells"],"prefix":"10.1016","volume":"196","author":[{"given":"Keita","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukimi","family":"Washizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Bonkobara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2012.12.016_b0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1292\/jvms.68.1343","article-title":"Establishment and biological characterization of canine histiocytic sarcoma cell lines","volume":"68","author":"Azakami","year":"2006","journal-title":"Journal of Veterinary Medical Science"},{"key":"10.1016\/j.tvjl.2012.12.016_b0010","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.tvjl.2012.12.016_b0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2011.192","article-title":"Tumor control versus adverse events with targeted anticancer therapies","volume":"9","author":"Keefe","year":"2011","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/j.tvjl.2012.12.016_b0020","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1535-7163.MCT-10-0096","article-title":"Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling","volume":"9","author":"Levitt","year":"2010","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.tvjl.2012.12.016_b0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.tcam.2009.02.002","article-title":"Tyrosine kinase inhibitors in veterinary medicine","volume":"24","author":"London","year":"2009","journal-title":"Topics in Companion Animal Medicine"},{"key":"10.1016\/j.tvjl.2012.12.016_b0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1354\/vp.43-5-632","article-title":"Canine hemophagocytic histiocytic sarcoma: A proliferative disorder of CD11d+ macrophages","volume":"43","author":"Moore","year":"2006","journal-title":"Veterinary Pathology"},{"key":"10.1016\/j.tvjl.2012.12.016_b0035","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.tvjl.2012.12.016_b0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.tvjl.2012.12.016_b0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1939-1676.2007.tb02937.x","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski","year":"2007","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2012.12.016_b0050","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clinical Therapeutics"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023312005436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023312005436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:27:19Z","timestamp":1761071239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023312005436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1090023312005436"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2012.12.016","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2012.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}